These data suggest that future pharmacological intervention targeting PolQ alone or in combination with PARP-1 and DNA damaging agents may have promise as an additional therapeutic strategy for HPV+-HNSCC. This evidence concerns the gene PARP1 and head and neck squamous cell carcinoma.